Mainland China’s regulatory evolution brings greater access to novel drugs
Clarivate
MAY 11, 2023
Over the past five years, healthcare leaders in Mainland China have made significant strides in their efforts to reduce lag time in availability of novel drugs versus western markets. No drugs are approved for the treatment of HLH and mortality rates are high (30-40%).
52 
Let's personalize your content